Business Context and Reporting Period
This Form 8-K filing by TherapeuticsMD, Inc. reports on the results of the 2016 Annual Meeting of Stockholders held on June 16, 2016. The filing details the voting outcomes for the election of directors, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events rather than a financial statement.
Material Changes and Voting Results
Three proposals were submitted to stockholders, and all received the necessary votes to be adopted:
- Proposal 1 (Election of Directors): Ten directors were elected. All nominees received zero votes "Against." Abstentions ranged from approximately 496,000 to 12.9 million votes depending on the nominee.
- Proposal 2 (Executive Compensation): A non-binding advisory vote on fiscal year 2015 compensation passed with 141,420,516 votes "For" and 3,552,760 votes "Against."
- Proposal 3 (Auditor Ratification): The appointment of Grant Thornton, LLP as the independent auditor for the fiscal year ending December 31, 2016, was ratified with 178,066,850 votes "For" and 355,259 votes "Against."
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the procedural outcomes of the annual meeting.
Investor Verification Checklist
- Verify the full list of elected directors and their tenure terms in the 2016 Proxy Statement.
- Review the 2016 Proxy Statement for details on the executive compensation package voted upon in Proposal 2.
- Confirm the scope of services and fees for Grant Thornton, LLP as the newly ratified auditor.
- Note that this filing does not contain financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.